Sultan® 500 SC Estland - Estnisch - Adama

sultan® 500 sc

adama - suspensioonikontsentraat - metasakloor - herbitsiidid

Raxone Europäische Union - Estnisch - EMA (European Medicines Agency)

raxone

chiesi farmaceutici s.p.a - idebenoon - optika atroofia, pärilik, leber - muud psychostimulants ja nootroopikumid, psychoanaleptics, - raxone on näidustatud leberi päriliku optilise neuropaatia (lhon) noorukite ja täiskasvanud patsientide nägemiskahjustuse raviks.

Fasenra Europäische Union - Estnisch - EMA (European Medicines Agency)

fasenra

astrazeneca ab - benralizumab - astma - ravimid hingamisteede obstruktiivsete haiguste, - fasenra on märgitud, et lisada hooldus ravi täiskasvanud patsientidel, kellel on raske eosinophilic astma puudulikult kontrollitud vaatamata suure annuse inhaleeritava kortikosteroide pluss pika toimeajaga ß-agonistide.

Apiguard taru ravimgeel Estland - Estnisch - Ravimiamet

apiguard taru ravimgeel

vita bee health limited - tümool - taru ravimgeel - 12,5g 50g 10tk

Abecma Europäische Union - Estnisch - EMA (European Medicines Agency)

abecma

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastilised ained - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Litfulo Europäische Union - Estnisch - EMA (European Medicines Agency)

litfulo

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - immunosupressandid - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.